Funders › AZ › Ben and Catherine Ivy Foundation › 2023
Grants paid by Ben and Catherine Ivy Foundation, tax year 2023
EIN 27-3322123 · Scottsdale, AZ · Form 990-PF, Part XV · NTEE T20
In tax year 2023, Ben and Catherine Ivy Foundation (EIN 27-3322123) reported 28 grants paid totaling $13,956,860. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2023
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2023 | St Joseph's Foundation Phoenix, AZ | B | $5,970,000 | paid | IVY BRAIN TUMOR CENTER AT BARROW NEUROLOGICAL INSTITUTE CAPITAL EXPENDITURES. | 202421929349101307 |
| 2023 | Neuro Trials LLC Phoenix, AZ | U | $3,800,935 | paid | MULTIPLE AWARDS:1) DEVELOPMENT OF TRIPLE-DRUG COCKTAILS TO INDUCE GLIOBLASTOMA.2) UCSF PRECLINICAL CORE FOR DRUG DEVELOPMENT AT THE IVY BRAIN TUMOR CENTER.3)10 YEAR IBTC GRANT4) MATCHING FUNDS NATIONAL GBM DAY | 202421929349101307 |
| 2023 | Society of St Vincent de Paul Phoenix, AZ | C | $380,000 | paid | CENTER FOR FAMILY WELLNESS ESTABLISHED TO FOCUS ON THE PREVENTION AND MANAGEMENT OF CHRONIC DISEASES THROUGH NUTRITION, PHYSICAL ACTIVITY AND OVERALL WELLNESS. ITS CULTURALLY GROUNDED BILINGUAL EDUCATION PROGRAMS ENCOURAGE THE WHOLE FAMILY TO PARTICIPATE. | 202421929349101307 |
| 2023 | Swedish Medical Center Seattle, WA | C | $300,500 | paid | ASSESS COMBINATIONS OF SMALL MOLECULES AND IMMUNOTHERAPIES FOR KILLING GLIOBLASTOMA TUMOR CELLS IN A PERSONALIZED EX VIVO ECOSYSTEM WITH INTACT TUMOR MICROENVIRONMENT USING MULTIPLEX IMMUNOCHEMISTRY AND SPATIAL MAPPING OF CELL TYPES. | 202421929349101307 |
| 2023 | University of Virginia Charlottesville, VA | U | $300,000 | paid | DEVELOP SMALL MOLECULE INHIBITORS OF A NEWLY IDENTIFIED ONCOGENE IN GLIOBLASTOMA. PMT 1 OF 2. | 202421929349101307 |
| 2023 | University of Virginia Charlottesville, VA | U | $300,000 | paid | DEVELOP AND DEPLOY STRATEGIES FOR LEVERAGING MRI-GUIDED FOCUSED ULTRASOUND THERAPY TO POTENTIATE CAR-T CELL THERAPY AGAINST ADULT HIGH-GRADE GLIOMAS. PMT 1 OF 2. | 202421929349101307 |
| 2023 | City of Hope Medical Center Duarte, CA | U | $300,000 | paid | PHASE I CLINICAL TRIAL TO EVALUATE THE FEASIBILITY, SAFETY, AND CLINICAL EFFICACY OF TGF-RESISTANT ILIRa2-CAR T CELLS FOR TREATMENT OF RECURRENT GLIOBLASTOMA. PMT #1 OF 2. | 202421929349101307 |
| 2023 | Mayo Clinic College of Medicine Rochester, MN | U | $300,000 | paid | EVALUATE CANDIDATE GLIOMA CSF PROTEOMIC SIGNATURES TO HELP UNDERSTAND AND MONITOR GLIOMA EVOLUTION IN LIVING PATIENTS DURING STANDARD OF CARE AND EXPERIMENTAL IMMUNOTHERAPY. PAYMENT 2 OF 2. | 202421929349101307 |
| 2023 | University of Tx Md Anderson Cancer Houston, TX | U | $300,000 | paid | PROJECT SEEKS TO PRECLINICALLY OPTIMIZE NOVEL THERAPEUTIC APPROACHES FOR ATRX-DEFICIENT MALIGNANT GLIOMAS TARGETING G-QUADRUPLEX DNA SECONDARY STRUCTURE. PAYMENT 2 OF 2. | 202421929349101307 |
| 2023 | Children's Hospital of Philadelphia Philadelphia, PA | B | $300,000 | paid | ENGINEERING A MULTI-ANTIGEN TARGETING CAR T THERAPY WITH CONFINED ACTIVITES WITHIN THE TUMOR MICROENVIRONMENT TO TREAT ANTIGENICALLY HETEROGENOUS ADULT GLIOBLASTOMA. | 202421929349101307 |
| 2023 | University of Virginia Charlottesville, VA | U | $300,000 | paid | DEVELOP AND TEST NEW THERAPIES FOR GLIOBLASTOMA USING MICORNAS. PMT 1 OF 2. | 202421929349101307 |
| 2023 | Mayo Clinic Jacksonville, FL | U | $300,000 | paid | IDENTIFY THE ONCOGENIC SIGNALING DEPENDENCIES THAT CHARACTERIZE EACH OF THE CELLULAR SUBPOPULATIONS THAT COMPRISE A GLIOBLASTOMA TUMOR, AND FROM THIS INFORMATION CONSTRUCT A NON-TOXIC COMBINATION OF KINASE INHIBITORS TO EFFECTIVELY TREAT THIS DISEASE. PAYMENT 2 OF 2. | 202421929349101307 |
| 2023 | Indiana University Foundation Bloomington, IN | C | $298,592 | paid | DETERMINE THE STRUCTURAL BASIS AND MOLECULAR MECHANISM OF ACTION OF SUM01 DEGRADERS IN TREATMENT OF GLIOBLASTOMA, ALONE AND IN COMBINATION WITH CURRENT STANDARD CHEMO AND RADIOTHERAPY. | 202421929349101307 |
| 2023 | Columbia University Irving Medical New York, NY | U | $250,000 | paid | TARGETING THE GLIOBLASTOMA MASTER REGULATOR CEBP A PHARMACOKINETICS AND PHARMACODYNAMICS SURGICAL STUDY OF ST101. PAYMENT 2 OF 2. | 202421929349101307 |
| 2023 | University of Michigan Ann Arbor, MI | U | $250,000 | paid | DEVELOP QUANTITATIVE METHODS TO ASSESS METHIONNINE METABOLISM AND TEST THE EFFICACY OF METHIONNE-DIRECTED THERAPEUTICS IN MOUSE MODELS AND PATIENTS WITH GLIOBLASTOMA. PMT 1 OF 2. | 202421929349101307 |
| 2023 | University of Tx Md Anderson Cancer Houston, TX | U | $250,000 | paid | DEVELOP SAFE AND POTENT DRUGS THAT CAN TURN THE TUMOR IMMUNE MICROENVIRONMENT FROM SUPPRESSIVE TO PERMISSIVE, THEREBY HELPING THE IMMUNE SYSTEM TO RECOGNIZE AND KILL GLIOBLASTOMA. PAYMENT 2 OF 2. | 202421929349101307 |
| 2023 | St Joseph's Foundation Phoenix, AZ | B | $135,000 | paid | supports patient care, medical education, research and community outreach at St. Joseph Hospital. | 202421929349101307 |
| 2023 | Damon Runyon Cancer Research Fdn New York, NY | U | $130,000 | paid | INVESTIGATION OF A BIOMARKER PHASE 2 STUDY TO EVALUATE TARGETED THERAPY HARBORING SPECIFIC GENETIC ALTERATIONS. 4TH AND FINAL PMT. | 202421929349101307 |
| 2023 | Arcs Foundation Artesia, CA | U | $8,800 | paid | ADVANCE SCIENCE AND TECHNOLOGY IN THE UNITED STATES BY PROVIDING AWARDS TO ACADEMICALLY OUTSTANDING US CITIZENS STUDYING TO COMPLETE DEGREES IN SCIENCE, ENGINEERING AND MEDICAL RESEARCH. | 202421929349101307 |
| 2023 | Common Spirit Health Foundation San Francisco, CA | U | $5,000 | paid | focused on making health equity a reality across the country through pioneering programs that ensure greater access to care, create community partnerships and participation and advocate for those who are vulnerable. | 202421929349101307 |
| 2023 | Leukemia Lymphoma Society Phoenix, AZ | U | $250 | paid | supports the development of new treatments for cancer and breaking down the barriers to care that patients often encounter. | 202421929349101307 |
| 2023 | University of Tx Md Anderson Cancer Houston, TX | U | -$843 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | Univ of Miami Miller School of Medi Miami, FL | U | -$1,480 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | University of Michigan Ann Arbor, MI | U | -$3,200 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | H Lee Moffitt Cancer Center Rochester, MN | U | -$5,872 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | Ut Southwestern Medical Center Dallas, TX | U | -$35,269 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | Emory University Atlanta, GA | U | -$51,233 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
| 2023 | Yale Cancer Center New Haven, CT | U | -$124,320 | paid | REFUND OF UNUSED FUNDS. | 202421929349101307 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.